Associated Papers
Stoichiometric transport of estrone 3-sulfate among genetic variants of OATP1A2 and OATP2B1 and structural analysis by molecular dynamics simulation: Impairment of gating mechanism in the unstable inward-open conformation of OATP2B1 (Asp215Val) significantly suppress the transport activity.
Akiyoshi T et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2025
Impact of genetic variants in the solute carrier (SLC) genes encoding drug uptake transporters on the response to anticancer chemotherapy.
Marin JJG et al.
Cancer Drug Resistance (alhambra, Calif.), 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Comparison of the transport kinetics of fexofenadine and its pH dependency among OATP1A2 genetic variants.
Han H et al.
Drug Metabolism and Pharmacokinetics, 2022
Comparison of the inhibitory properties of the fruit component naringenin and its glycosides against OATP1A2 genetic variants.
Araki N et al.
Drug Metabolism and Pharmacokinetics, 2022
Genetic variability and population diversity of the human SLCO (OATP) transporter family.
Zhang B et al.
Pharmacological Research, 2019
The SLCO1A2 -189_-188InsA polymorphism reduces clearance of rocuronium in patients submitted to elective surgeries.
Costa ACC et al.
European Journal of Clinical Pharmacology, 2017
Recent advance in the pharmacogenomics of human Solute Carrier Transporters (SLCs) in drug disposition.
Zhou F et al.
Advanced Drug Delivery Reviews, 2017
Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance.
Lee HH et al.
Molecular Pharmacology, 2017
Genetic polymorphisms and function of the organic anion-transporting polypeptide 1A2 and its clinical relevance in drug disposition.
Zhou Y et al.
Pharmacology, 2015
Environmental and genetic factors affecting transport of imatinib by OATP1A2.
Eechoute K et al.
Clinical Pharmacology and Therapeutics, 2011
Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants.
Badagnani I et al.
The Journal of Pharmacology and Experimental Therapeutics, 2006
Implications of genetic polymorphisms in drug transporters for pharmacotherapy.
Kerb R
Cancer Letters, 2006
Pharmacogenomics of human OATP transporters.
König J et al.
Naunyn-schmiedeberg's Archives of Pharmacology, 2006
Membrane transporter proteins: a challenge for CNS drug development.
Girardin F
Dialogues in Clinical Neuroscience, 2006
Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry.
Lee W et al.
The Journal of Biological Chemistry, 2005